Find out more about self-funded PhD projects in areas of biomedical science.
We already have supervisors active and engaged in the research topic in our School of Life Sciences.
Fixed term contract for 3 years, commencing September 2026.
Bursary of £21,805 per annum and a full fee-waiver for tuition fees, funded by Sedgwick.
Closing date: 1 July 2026
Interview date: TBC July 2026
About Anglia Ruskin University:
Anglia Ruskin is a vibrant workplace and our university is recognised both nationally and internationally. We have ambitious plans for the future, and we are determined that our students and staff will realise their full potential. Our main campuses in the cities of Cambridge, Chelmsford, London and Peterborough have been transformed with major capital investment. With an annual turnover of over £200m, we are a major force for higher education and one of the largest universities in the East of England.
About the position:
The calcification of arteries is a significant risk factor in the development of heart attacks and stroke. Identifying new pathways and novel pharmacological targets that prevent this process could therefore reduce the risk of cardiovascular disease.
Platelet activation leading to pathophysiological thrombosis requires the induction of intracellular signalling pathways. Investigation of the roles of members of these pathways is restricted by both the resistance of platelets to genetic manipulation, and by a lack of agonists and antagonists. This project aims to address these problems by developing new technologies to investigate the potential to introduce full length functional proteins into the platelet cytosol.
The new technology will utilise Protein Transduction Domains (PTDs) to introduce bioactive proteins into platelets, which has received little research attention. The scheme is to generate recombinant constitutively active and dominant negative mutant proteins, each tagged with a PTD. Transduction of the constitutively active variant into platelets is expected to activate the cognate signalling pathway, resulting in downstream activatory responses.
The project has three stages, The first stage of this project will be to investigate different cell penetrating technologies, to determine which is the most effective in platelets. Following this, a recombinant constitutively active Rab1b protein will be generated, and its effect on platelet activation will be investigated. Finally, this technology will be used to investigate the role of platelet GTPases, for which no role has yet been ascribed.
About the Studentship:
A 3-year studentship is offered, intended to start in September 2026, providing a tax-free stipend of £21,805 per annum plus tuition fees, funded by Sedgwick.
Project location: Cambridge campus. Prospective candidates who would not be Cambridge-based are encouraged to contact the principal supervisor prior to application (contact details below).
Candidates for this PhD Studentship must demonstrate outstanding qualities and be motivated to complete a PhD within 3 years.
Qualifications:
Applicants should have a minimum of a 2.1 Honours degree in a relevant discipline. An IELTS (Academic) score of 6.5 minimum (or equivalent) is essential for candidates for whom English is not their first language.
In addition to satisfying basic entry criteria, the University will look closely at the qualities, skills, and background of each candidate and what they can bring to their chosen research project in order to ensure successful and timely completion.
As the project will be using human blood, applicants should be HepB vaccinated, and have a HepB antibody titre test prior to starting the project.
How to apply:
To apply, please visit Biomedical Science PhD, click 'Apply online' and complete the application form for full-time study with a start date of September 2026. Please ensure the reference 'PhD Studentship: Addressing the role of the GTPases in human platelet signal transduction cascades using novel recombinant protein tools' is clearly stated on the application form, under the title ‘Outline of your proposed research’.
Within this section of the application form, applicants should include a 500-word outline of the skills that they would bring to this research project and detail any previous relevant experience.
Interested applicants should direct initial queries about the project to Professor Nicholas Pugh via email: [email protected]. For enquiries regarding the process and eligibility please contact [email protected].
Interviews are scheduled to take place in July 2026.
We value diversity at Anglia Ruskin University and welcome applications from all sections of the community.
Closing Date 1 July 2026.
Fixed term contract for 3 years, commencing September 2026.
Bursary of £21,805 per annum and a full fee-waiver for tuition fees, funded by Sedgwick.
Closing date: 1 July 2026
Interview date: TBC July 2026
About Anglia Ruskin University:
Anglia Ruskin is a vibrant workplace and our university is recognised both nationally and internationally. We have ambitious plans for the future, and we are determined that our students and staff will realise their full potential. Our main campuses in the cities of Cambridge, Chelmsford, London and Peterborough have been transformed with major capital investment. With an annual turnover of over £200m, we are a major force for higher education and one of the largest universities in the East of England.
About the position:
Pseudomonas aeruginosa was designated a “critical priority pathogen” by the WHO reflecting its ubiquity in the built environment, arsenal of virulence factors, and resistance to multiple antibiotics. Of the 160 antibiotics currently in clinical use, some strains of P. aeruginosa are resistant to all of these. A particular threat is the emergence of resistance against carbapenems, which remain a mainstay of antibiotic use globally. Resistance in P. aeruginosa is multifactorial, and known mechanisms include diminished outer membrane permeability to carbapenems, antibiotic efflux pumps, and horizontal acquisition of extended spectrum beta-lactamases. However, additional mechanisms have been implicated, the evolutionary pathway(s) of carbapenem resistance – and their associated fitness costs - remains unclear.
This PhD project will use a novel inducible hypermutator strain of P. aeruginosa in adaptive laboratory evolution experiments to systematically select carbapenem-resistant mutants under controlled selective pressure. By coupling experimental evolution with whole-genome sequencing and targeted genetic validation, the work aims to identify and confirm novel mechanisms of carbapenem resistance advancing our understanding of resistance evolution with direct clinical relevance.
About the Studentship:
A 3-year studentship is offered, intended to start in September 2026, providing a tax-free stipend of £21,805 per annum plus tuition fees, funded by Sedgwick.
Project location: Cambridge campus. Prospective candidates who would not be Cambridge-based are encouraged to contact the principal supervisor prior to application (contact details below).
Candidates for this PhD Studentship must demonstrate outstanding qualities and be motivated to complete a PhD within 3 years.
Qualifications:
Applicants should have a minimum of a 2.1 Honours degree in a relevant discipline. An IELTS (Academic) score of 6.5 minimum (or equivalent) is essential for candidates for whom English is not their first language.
In addition to satisfying basic entry criteria, the University will look closely at the qualities, skills, and background of each candidate and what they can bring to their chosen research project in order to ensure successful and timely completion.
Applicants should have experience of basic microbiological techniques.
How to apply:
To apply, please visit Biomedical Science PhD, click 'Apply online' and complete the application form for full-time study with a start date of September 2026. Please ensure the reference 'PhD Studentship: Identification of novel mechanisms of Pseudomonas aeruginosa carbapenem resistance using adaptive laboratory evolution studies' is clearly stated on the application form, under the title ‘Outline of your proposed research’.
Within this section of the application form, applicants should include a 500-word outline of the skills that they would bring to this research project and detail any previous relevant experience.
Interested applicants should direct initial queries about the project to Dr Caray Walker via email: [email protected]. For enquiries regarding the process and eligibility please contact [email protected].
Interviews are scheduled to take place in July 2026.
We value diversity at Anglia Ruskin University and welcome applications from all sections of the community.
Closing Date 1 July 2026.
Prof David Leake (University of Reading)
Translational Biomedicine
Background: Macrophages play a critical role in homeostasis and diseases. They can change their phenotype to perform differential activities in different phases of inflammatory response.
Polarized macrophages are broadly classified into two groups:
It has been demonstrated that M1/M2 switch plays critical role in inflammation which is dependent on various factors such as bioavailability of different subsets of monocytes and macrophages, sequential monocytes recruitment into the tissue in the process of inflammation or response to different conditions. Furthermore, the misbalance of M1/M2 switch can lead to chronic inflammatory diseases. Undoubtedly the generation of novel anti-inflammatory drugs regulating M1/M2 switch is an important step for pharmacological intervention of chronic inflammatory-based diseases. Unfortunately, the current drug screening strategies are not based on macrophage polarization. The development of a phenotypic macrophage high-throughput assay will provide a platform for screening of pro or anti-inflammatory properties of the candidate molecule (preclinical drug validation) or FDA approved drugs library and selected compound libraries with known anti-inflammatory activity (clinical drug validation).
Main goal and objectives: The main goal of the study is to develop and validate a novel phenotypic macrophage high-throughput cell-based assay for anti-inflammatory drug screening activity. The two main objectives are:
Methodology: Cell culture and cell-based essays, western blotting, ELISA approaches.
Collaborations: This project is based on academic and industrial collaborations with Reading University and Innaxon, UK respectively.
Outcomes: Results from this project will evaluate the potential of the phenotypic macrophage high-throughput assay for drug screening as well as provide important information about the effect of the candidate molecules on macrophage polarisation and will contribute to their preclinical/clinical validation. This will represent a finding of great public and commercial impact as currently there are no macrophage cell-based phenotypic assays for drug screening. The proposed project will have a commercial value and we plan to secure protection of the arising intellectual property.
This project is self-funded.
Details of studentships for which funding is available are selected by a competitive process and are advertised on our jobs website as they become available.
If you wish to be considered for this project, you will need to apply for our Biomedical Science PhD. In the section of the application form entitled 'Outline research proposal', please quote the above title and include a research proposal.
Biomedicine and Environmental Pollution
Background: Plastic production has risen from 1.5 to 450 million tons annually since the 1950’s and is set to double by 2045. The total weight of plastic on Earth already exceeds the overall mass of all land and marine animals and plastic pollutants have altered Earth’s processes to an extent that exceeds the threshold under which humanity can survive in the future (i.e., surpassing the planetary boundary). Micro and nano plastics are the most abundant form of solid waste on Earth on average, humans are exposed to an estimated 39,000 to 121,000 particles per year via ingestion of contaminated food, beverages and drinking water via inhalation. The World Health Organization recently concluded that although NMP may pose a threat to human health, we need more evidence on their potential effects, especially concerning the lower size range (nano) of particles. In response to concerns about conventional plastics, demand for biodegradable bio-based plastics is increasing. Many of these plastics do not rapidly degrade in the natural environment and can persist as NMP and can have the same negative impacts as conventional plastics. The impacts of biodegradable NMP on human health has not been tested. Based on current knowledge on NMP toxicity and hazard there are substantial gaps and future research needs. Most of the studies are based on NMP without any characterisation of their physico-chemical properties (size, shape, charge etc.) which create difficulties in interpretation of their toxicological profile. Secondly, a high number of studies have employed very high concentrations of NMP which do not reflect on real environmental conditions. Although toxicological studies have shown that NMP exposure may lead to health risk there is a lack of evidence that this can negatively affect the immune system which is primary related to measurement of human health risks. Therefore, future research must be focused on biokinetics and proinflammatory and toxicological properties of environmentally relevant NMP with well characterised physico-chemical properties consistent with their environmental degradation.
Main goal: This project will investigate the proinflammatory and toxicological properties on NMP generated from conventional and future biodegradable plastics.
There are three main objectives:
Methodology: Cell culture and cell-based essays, western blotting, ELISA, Flow Cytometry and antibody array approaches.
Collaborations: This project is based on national and international academic collaborations with University of Milano-Bicocca and Reading University.
Outcomes: The results from this project will be used to consolidate international networking and national and international collaborations and to apply for EU Horizon (Micro- and nano-plastics in our environment: understanding exposures and impacts on human health) and will build on the success of the REF2027 Impact Case Study by Dr Green “Reducing the impacts of single use plastics”. This research also compared conventional and biodegradable plastics but on environmental compartments as opposed to human health.
This project is self-funded.
Details of studentships for which funding is available are selected by a competitive process and are advertised on our jobs website as they become available.
If you wish to be considered for this project, you will need to apply for our Biomedical Science PhD. In the section of the application form entitled 'Outline research proposal', please quote the above title and include a research proposal.